TransCode Therapeutics logo
TransCode Therapeutics
RNAZ | NASDAQ
Chart Builder DCF Calculator
$1.35
+$0.03 (+2.27%)
At close: Nov 16, 2026, 4:00 PM ET
$1.37
+$0.02 (+1.48%)
After-hours: Nov 16, 2026, 7:30 PM ET

TransCode Therapeutics Company Profile

Company profile explained

Company Profile

TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.

Key Executives

Name Position
Philippe Calais Chief Executive Officer & Executive Chairman of the Board
John A. Tattory Interim Chief Financial Officer
Anna Moore Scientific Co-Founder, Scientific Advisor & Chair of Scientific Advisory Board
Daniel R. Vlock Chief Medical Officer
Michel Janicot Consulting Head of Translational Science
Susan Duggan Senior Vice President of Operations
Thomas A. Fitzgerald CFO, Secretary, President, VP of Administration & Director
Zdravka Medarova Scientific Co-Founder & Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 28, 2026 8-K Current Report
Oct 01, 2026 8-K Current Report
Sep 28, 2026 8-K Current Report
Sep 21, 2026 3 Filing
Sep 11, 2026 4 Filing
Sep 11, 2026 8-K Current Report
Aug 14, 2026 10-Q Quarterly Report
Aug 05, 2026 4 Filing
Aug 05, 2026 3 Filing
Aug 03, 2026 SC 13D/A [Amend] Filing
View All SEC Filings ➞
TransCode Therapeutics
TransCode Therapeutics logo
Country United States
IPO Date Jul 8, 2021
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Philippe Calais

Contact Details

6 Liberty Square Boston, Massachusetts 02109 United States

Stock Details

Ticker Symbol RNAZ
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001829635
CUSIP Number 89357L501
ISIN Number US89357L5012
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.